CELLCEPT (mycophenolate mofetil)
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
ROCHE
Indication
Prevention of cardiac transplant rejection
Prevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation. Read more about Prevention of cardiac transplant rejection
112 drugs 69 manufacturers
Drugs that treat it
Common Prevention of cardiac transplant rejection therapies.
MYCOPHENOLATE MOFETIL
IMMUNOSUPPRESSIVE INOSINE MONOPHOSPHATE DEHYDROGENASE INHIB.·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
TEVA USA
TACROLIMUS
IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
SANDOZ
PROGRAF (tacrolimus)
IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
Astellas Pharma US
NEORAL (cyclosporine, modified)
ANTIPSORIATICS·SEVERE RECALCITRANT PSORIASIS·+4
Novartis Pharmaceuticals
NEORAL (cyclosporine, modified)
ANTIPSORIATICS·SEVERE RECALCITRANT PSORIASIS·+4
Novartis Pharmaceuticals
CELLCEPT INTRAVENOUS (mycophenolate mofetil HCl)
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
ROCHE
GENGRAF (cyclosporine, modified)
ANTIPSORIATICS·SEVERE RECALCITRANT PSORIASIS·+4
ABBOTT
GENGRAF (cyclosporine, modified)
ANTIPSORIATICS·SEVERE RECALCITRANT PSORIASIS·+4
ABBOTT
Filter & compare in the drug finder →Opens the drug finder with Prevention of cardiac transplant rejection preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation.
This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy.
Pathophysiologically, unmitigated rejection leads to myocardial lymphocytic infiltration, microvascular endothelial injury, progressive myocardial necrosis, and eventual graft dysfunction or failure.
Prophylaxis preserves donor cardiac function by suppressing alloimmune recognition and effector pathways throughout induction and long-term maintenance phases.
- nih.gov
Prevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation Pathophysiologically, unmitigated rejection leads to myocardial lymphocytic infiltration, microvascular endothelial injury, progressive myocardial necrosis, and eventual graft dysfunction or failure
- e-heartfailure.org
Prevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation
- nih.gov
This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy Prophylaxis preserves donor cardiac function by suppressing alloimmune recognition and effector pathways throughout induction and long-term maintenance phases
- cedars-sinai.org
This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy Pathophysiologically, unmitigated rejection leads to myocardial lymphocytic infiltration, microvascular endothelial injury, progressive myocardial necrosis, and eventual graft...
- intechopen.com
This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy
- ovid.com
This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy
- nih.gov
Prophylaxis preserves donor cardiac function by suppressing alloimmune recognition and effector pathways throughout induction and long-term maintenance phases
Personalize your experience
Follow Prevention of cardiac transplant rejection and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.